Chlorpromazine (Thorazine) is a medication that plays a role in managing symptoms across several therapeutic areas, primarily addressing conditions marked by heightened distress and disruptive manifestations. It is commonly utilized to help manage severe psychiatric and specific non-psychiatric issues.

---

Symptom Relief and Therapeutic Scope

The primary therapeutic use involves supporting the management of acute psychotic and severe behavioral symptoms. It is applied in clinical settings that involve acute or unstable symptom patterns, such as those seen in schizophrenia and manic episodes of bipolar disorder. It is considered relevant for managing severe behavioral problems in children aged 1 to 12 years. Less commonly, it is applied in addressing physical symptoms that may resist typical treatment, including severe, persistent nausea and vomiting and intractable hiccups (singultus).

This use supports patients by:

contributing to easing the overall symptom load and helping to maintain a sense of stability when symptoms are more noticeable.

By addressing these severe manifestations, Chlorpromazine supports general well-being during symptomatic phases and contributes to easing distress during difficult episodes.

---

Quick Fact: Relief for Difficult-to-Manage Symptoms

Quick Fact: Relief for Intractable Hiccups

Chlorpromazine is relevant for easing symptoms that are difficult to manage, being commonly used to help with persistent singultus—a condition where chronic hiccups fail to respond to standard medical treatments. This application provides supportive relief when symptoms are difficult to tolerate.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Chlorpromazine (Thorazine)

---

The decision to use chlorpromazine is strictly governed by authoritative regulatory guidelines, which define specific eligible and non-eligible patient populations.

Contraindicated Populations (Must Not Use)

Use of chlorpromazine is absolutely forbidden (contraindicated) in the following circumstances, as documented by official government regulatory sources:

• Central Nervous System (CNS) Depression: Patients in a comatose state or those with severe CNS depression, particularly due to large amounts of CNS depressants like alcohol or narcotics.
• Circulatory/Hematologic Conditions: Individuals experiencing circulatory collapse or those with bone marrow depression.
• Hypersensitivity: Patients with a documented known hypersensitivity or allergy to phenothiazines, chlorpromazine, or any of its inactive ingredients.

---

Populations with Restricted or Non-Established Use

Use is restricted or not recommended in several specific groups:

• Elderly Patients: The medicine is not approved for the treatment of dementia-related psychosis in elderly patients due to an officially documented increased risk of death in this population.
• Infants: Safety and effectiveness have not been established for use in infants under 6 months of age.
• Pregnancy and Breastfeeding: Use during the third trimester of pregnancy is restricted due to the risk of extrapyramidal and/or withdrawal symptoms in the neonate. Use during breastfeeding is generally not recommended.
• Pre-existing Conditions: Caution is required, and use may be restricted, in patients with conditions such as severe cardiovascular, liver, or renal disease, or epilepsy.

Interactions with other medicines and products

Thorazine (chlorpromazine) can interact with many other medicines and substances, primarily by increasing sedative and blood pressure effects, or by affecting the heart’s rhythm.

Contraindicated Combinations (Do Not Combine)

Co-administration with medicines known to prolong the QTc interval is generally contraindicated due to a high risk of serious heart rhythm abnormalities, including Torsade de pointes. Specific examples include certain antiarrhythmics (such as disopyramide, ibutilide, quinidine, sotalol) and other QTc-prolonging agents (like pimozide or pentamidine). Use is also contraindicated with Amisulpride due to the increased risk of Neuroleptic Malignant Syndrome, with the imaging agent Metrizamide (due to seizure risk), and with certain strong CYP2D6 inhibitors like Mavorixafor.

High-Risk Pharmacodynamic Interactions

• CNS Depressants: Combining Thorazine with central nervous system (CNS) depressants such as alcohol, opioids, barbiturates, or sedatives may result in additive or potentiated effects, significantly increasing drowsiness, sedation, and low blood pressure (hypotension).
• Antihypertensive Agents: Thorazine can cause hypotension on its own, and combining it with other blood pressure-lowering agents may lead to dangerously low blood pressure. Adrenaline (Epinephrine) should be avoided for treating hypotension induced by Thorazine, as its pressor effect may be reversed, leading to a further drop in blood pressure.
• Anticholinergics: Concomitant use with anticholinergic drugs can lead to increased side effects such as severe constipation and urinary retention.

Dopamine Receptor Antagonism

Thorazine (chlorpromazine) exerts its primary action by functioning as a non-selective antagonist at postsynaptic dopamine D2 receptors within the central nervous system, particularly in the mesolimbic pathway. This receptor blockade modifies key pathways associated with high dopaminergic signaling. This engagement initiates a cascade that results in altered neurotransmitter flow and subsequent modification of neuronal signaling across the targeted pathways.

---

Multi-Receptor Pathway Modulation

The drug also demonstrates significant activity as an antagonist across several other neurotransmitter systems, including serotonin ( 5-HT2), histamine ( H1), alpha-adrenergic, and muscarinic acetylcholine receptors. This broad, multi-target binding profile affects diverse signaling sequences. By influencing the binding affinity of multiple neurotransmitter mediators, the compound induces modified physiological responses within pathways governing arousal and autonomic function.

---

Systemic Physiological Consequence

Through the combined influence on dopamine and secondary receptors, Thorazine modifies the activity of various physiological processes driven by distinct signaling patterns at subcortical levels. This multifaceted engagement with different mechanistic domains results in the modification of heightened physiological responses across the central nervous system, influencing the resulting spectrum of effects.

How to Use Thorazine (Chlorpromazine)

Chlorpromazine administration is governed by a structured protocol that specifies the route, dosage, and adjustment pattern. The medicine is primarily taken orally as tablets or solution for routine use, but it is also approved for administration by deep intramuscular (IM) injection for acute control, or by rectal suppository when oral intake is not feasible. The intravenous (IV) route is reserved for specific, highly restricted contexts.

Treatment must begin with low starting doses, such as 10 to 25 mg, typically taken in divided doses two to four times a day. The dosage is then gradually increased in small increments over time until the patient achieves the individual maintenance level. Standard maintenance dosage for prolonged use usually ranges from 75 mg to 300 mg daily, although higher amounts are sanctioned for severe acute episodes.

Specific procedural conditions must be followed for parenteral administration: The IV injectable solution must be diluted before use, and patients are directed to lie flat (supine) and be observed for at least 30 minutes after receiving an IM or IV dose. For certain populations, dosing requires mandatory modification: Older or debilitated adults must be initiated on one-third to one-half the usual adult dose with more gradual increases, and pediatric dosing is calculated based on body weight, with maximum daily doses applying to different age groups. After controlling acute symptoms, the effective dose is sustained for two weeks, followed by a gradual reduction to the lowest amount required for long-term management.

Research evidence / Overview of studies for Thorazine

---

## Evidence for Use in Psychotic Disorders (e.g., Schizophrenia)

Research for Chlorpromazine in conditions like schizophrenia and other psychotic disorders includes numerous Randomized Controlled Trials (RCTs) and subsequent systematic reviews. This body of research was used in research exploring how symptoms change over time in adults. Studies monitored various outcomes related to global clinical change and symptom intensity, as well as tracking the frequency of relapse.

The available evidence base reported outcomes primarily relevant to short-term stabilization (often 8 weeks or less). Findings describe patterns observed in these studies, where treatment was evaluated during periods of heightened symptom activity. However, the quality of much of the evidence is frequently cited as being low or very low due to reliance on older study designs and reporting flaws. Limited information is available for long-term functional outcomes and quality of life.

---

## Evidence for Use in Manic Episodes

This application was evaluated in studies conducted during periods of increased symptom activity in adults experiencing acute manic episodes of bipolar disorder. The research base includes Randomized Controlled Trials (RCTs) used in regulatory submissions. The trials monitored outcomes related to acute excitement and aggression. This evidence base is categorized as moderate, reflecting documentation from earlier trials. Follow-up durations were limited, typically focusing on immediate stabilization, and long-term effects are not fully established for sustained management of the manic phase.

---

## Evidence for Management of Severe Behavioral Problems in Children

Research exploring the use of Chlorpromazine for severe behavioral problems focuses on children aged 1 to 12 years. The evidence is derived from regulatory submission data and small clinical case studies, which monitored the level of short-term behavioral stabilization. Findings describe patterns observed in these small trials. The evidence for this application is limited due to a scarcity of supporting data from modern, high-quality, large-scale RCTs.

---

## Evidence for Non-Psychiatric Symptoms

Research has also explored the use in specific non-psychiatric conditions: intractable hiccups (persistent singultus) and severe nausea and vomiting. For intractable hiccups, the evidence base is primarily composed of Case Reports and small, uncontrolled studies. This evidence is generally characterized as low, and certainty remains low. For severe nausea and vomiting, evidence is derived from older clinical trials. While categorized as moderate, the available studies often lack the methodological rigor of current comparative trials.

---

## Long-Term Research and Durability of Outcomes

Studies monitored relapse and discontinuation over defined time intervals, with some follow-up durations extending up to two years. However, long-term effects are not fully established. Limited information is available for long-term outcomes, and the evidence quality varies across studies.

---

## Evidence in Specific Patient Groups

Research has specifically been evaluated in children aged 1 to 12 years for acute behavioral problems. The results apply only to the populations studied in those trials. For other groups, such as older adults or individuals with specific comorbidities, dedicated research focusing on this medication remains insufficient.

---

## Research Gaps and Unanswered Questions

The scientific community notes several key limitations in the existing evidence base. The quality of the original trial evidence varies across studies and often includes older methodologies and modest sample sizes, and the data itself often exhibits heterogeneity. Comparative evidence against the full spectrum of newer treatment options is lacking. Research exploring patient-reported outcomes remains limited. Certainty remains low in certain non-psychiatric and pediatric applications. Studies help show what has been observed so far, but these findings describe group patterns and do not determine whether an individual will respond similarly.

How to Store and Dispose of Thorazine (Chlorpromazine)

Storage Requirements

Thorazine (chlorpromazine) must be stored at room temperature, which regulatory documents often specify as not above 25°C, and kept away from excess heat and moisture. Due to the drug’s light sensitivity, it must be protected from light exposure to prevent decomposition and color change. The medication must be kept in its original container, which should remain tightly closed at all times.

Child Safety and Disposal

This medication must be stored out of the sight and reach of children to prevent accidental ingestion. For disposal, any unused product must be handled in accordance with local requirements. If a drug take-back program is unavailable, unused medication should be mixed with an undesirable substance (such as kitty litter) and sealed in a container before being thrown in the household trash; the drug must not be flushed down the toilet.